Donepezil hydrochloride + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Attention Impairment

Conditions

Attention Impairment

Trial Timeline

Jul 2, 2008 → May 26, 2009

NCT ID

NCT00688376

About Donepezil hydrochloride + Placebo

Donepezil hydrochloride + Placebo is a phase 3 stage product being developed by Eisai for Attention Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00688376. Target conditions include Attention Impairment.

What happened to similar drugs?

20 of 20 similar drugs in Attention Impairment were approved

Approved (20) Terminated (3) Active (0)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine hydrochloride + PlaceboEli LillyApproved

✅Atomoxetine + PlaceboEli LillyApproved

✅AtomoxetineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00688376	Phase 3	Completed	Jul 2, 2008	May 26, 2009	Attention Impairment
NCT00293176	Approved	Completed	Dec 1, 2003	Mar 1, 2007	Memory Loss

Competing Products

20 competing products in Attention Impairment

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine + Placebo	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	35
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Phase 3	40
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine hydrochloride + Placebo	Eli Lilly	Approved	43
CLONICEL (Clonidine HCl sustained release)	Shionogi	Phase 3	40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)	Eli Lilly	Phase 2/3	38
Atomoxetine + Placebo	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Pre-clinical	26
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Placebo	Eli Lilly	Approved	43
atomoxetine	Eli Lilly	Phase 3	40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine Hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo	Eli Lilly	Phase 3	40